Association between SLCO1B1, apolipoprotein E and ABCG2 genes and lipid response to rosuvastatin: a meta-analysis.

IF 1.6 3区医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Pharmacogenetics and genomics Pub Date : 2026-01-21 DOI:10.1097/FPC.0000000000000592

Jianhai Li, Yongkun Deng, Yong Lai, Lei Li, Limei Yu, Huiyou Li, Zhaohen Yin, Lingyan Liu

{"title":"Association between SLCO1B1, apolipoprotein E and ABCG2 genes and lipid response to rosuvastatin: a meta-analysis.","authors":"Jianhai Li, Yongkun Deng, Yong Lai, Lei Li, Limei Yu, Huiyou Li, Zhaohen Yin, Lingyan Liu","doi":"10.1097/FPC.0000000000000592","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the effects of SLCO1B1, apolipoprotein E (APOE) and ABCG2 gene polymorphisms on the lipid-modulating efficacy of rosuvastatin.Methods: Systematic searches were conducted in PubMed, Cochrane Library, Embase, Web of Science, PharmGKB, CNKI, VIP, and Wanfang databases (from database establishment to 1 March 2025). Studies on the correlation between SLCO1B1, APOE, ABCG2 gene polymorphisms and the lipid-modulating efficacy of rosuvastatin were collected, and meta-analysis was performed using RevMan 5.4 software.Results: A total of 16 studies involving 6167 patients were included, covering APOE (p.C130R/rs429358, p.R176C/rs741), SLCO1B1 (p.V174A/rs4149056, p.N130D/rs2306283), and ABCG2 (p.Q141K/rs2231142) genes. The results showed that SLCO1B1 [AG+GG vs. AA, mean difference = -4.36, 95% confidence interval (CI): -7.92 to -0.80, P = 0.02], APOE (E2 vs. E3, mean difference = -5.58, 95% CI: -8.04 to -2.51, P < 0.00001] and ABCG2 (CA+AA vs. CC, mean difference = -7.07, 95% CI: -9.47 to -4.68, P < 0.00001) genotypes all significantly affected statin-induced low-density lipoprotein cholesterol (LDL-C) reduction; patients with ABCG2 CA+AA genotype had statistically significant differences in total cholesterol level changes (mean difference = -7.15, 95% CI: -8.78 to -5.53) and triglyceride level changes (mean difference = -7.37, 95% CI: -10.91 to -3.83) (both P < 0.05).Conclusion: The lipid-lowering efficacy of rosuvastatin (especially the reduction of LDL-C level) is significantly affected by the polymorphisms of SLCO1B1 (c.388A>G), ApoE (c.388T>C, c.526C>T) and ABCG2 (c.421C>A) genes.","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007914/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenetics and genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FPC.0000000000000592","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the effects of SLCO1B1, apolipoprotein E (APOE) and ABCG2 gene polymorphisms on the lipid-modulating efficacy of rosuvastatin.

Methods: Systematic searches were conducted in PubMed, Cochrane Library, Embase, Web of Science, PharmGKB, CNKI, VIP, and Wanfang databases (from database establishment to 1 March 2025). Studies on the correlation between SLCO1B1, APOE, ABCG2 gene polymorphisms and the lipid-modulating efficacy of rosuvastatin were collected, and meta-analysis was performed using RevMan 5.4 software.

Results: A total of 16 studies involving 6167 patients were included, covering APOE (p.C130R/rs429358, p.R176C/rs741), SLCO1B1 (p.V174A/rs4149056, p.N130D/rs2306283), and ABCG2 (p.Q141K/rs2231142) genes. The results showed that SLCO1B1 [AG+GG vs. AA, mean difference = -4.36, 95% confidence interval (CI): -7.92 to -0.80, P = 0.02], APOE (E2 vs. E3, mean difference = -5.58, 95% CI: -8.04 to -2.51, P < 0.00001] and ABCG2 (CA+AA vs. CC, mean difference = -7.07, 95% CI: -9.47 to -4.68, P < 0.00001) genotypes all significantly affected statin-induced low-density lipoprotein cholesterol (LDL-C) reduction; patients with ABCG2 CA+AA genotype had statistically significant differences in total cholesterol level changes (mean difference = -7.15, 95% CI: -8.78 to -5.53) and triglyceride level changes (mean difference = -7.37, 95% CI: -10.91 to -3.83) (both P < 0.05).

Conclusion: The lipid-lowering efficacy of rosuvastatin (especially the reduction of LDL-C level) is significantly affected by the polymorphisms of SLCO1B1 (c.388A>G), ApoE (c.388T>C, c.526C>T) and ABCG2 (c.421C>A) genes.

查看原文本刊更多论文

SLCO1B1、载脂蛋白E和ABCG2基因与瑞舒伐他汀脂质反应之间的关联：一项荟萃分析

目的：探讨SLCO1B1、载脂蛋白E （APOE）和ABCG2基因多态性对瑞舒伐他汀降脂效果的影响。方法：系统检索PubMed、Cochrane Library、Embase、Web of Science、PharmGKB、CNKI、VIP、万方等数据库（数据库建立至2025年3月1日）。收集SLCO1B1、APOE、ABCG2基因多态性与瑞舒伐他汀降脂疗效的相关性研究，采用RevMan 5.4软件进行meta分析。结果：共纳入16项研究，涉及6167例患者，涵盖APOE （p.C130R/rs429358、p.R176C/rs741）、SLCO1B1 （p.p v174a /rs4149056、p.N130D/rs2306283）和ABCG2 （p.p q141k /rs2231142）基因。结果显示，SLCO1B1 [AG+GG vs. AA，平均差值= -4.36,95%可信区间（CI）： -7.92 ~ -0.80, P = 0.02]、APOE (E2 vs. E3，平均差值= -5.58,95% CI: -8.04 ~ -2.51, P < 0.00001]和ABCG2 （CA+AA vs. CC，平均差值= -7.07,95% CI: -9.47 ~ -4.68, P < 0.00001）基因型均显著影响他汀类药物诱导的低密度脂蛋白胆固醇（LDL-C）降低；ABCG2 CA+AA基因型患者总胆固醇水平变化（平均差异= -7.15,95% CI: -8.78 ~ -5.53）和甘油三酯水平变化（平均差异= -7.37,95% CI: -10.91 ~ -3.83）差异有统计学意义（均P < 0.05）。结论：瑞舒伐他汀的降脂效果（尤其是降低LDL-C水平）受SLCO1B1 （C . 388a >G）、ApoE （C . 388t >C、C . 526c >T）和ABCG2 （C . 421c >A）基因多态性的显著影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenetics and genomics 医学-生物工程与应用微生物

CiteScore

3.20

自引率

3.80%

发文量

审稿时长

3 months

期刊介绍： Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals. The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology. Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.